Organisation paid for research Program year 2025 Source: CMS Open Payments

MD Anderson

Neither a doctor nor a teaching hospital

Research payments

$4,723,592

277 payments

Through program year 2025, MD Anderson is reported as receiving $4,723,592 in research payments, across 277 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,116,502	12
2024	Research	$3,000,338	178
2023	Research	$557,418	61
2022	Research	$5,409	23
2020	Research	$653	1
2019	Research	$43,271	2

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $2,500,917 5 payments
GlaxoSmithKline, LLC. $2,078,908 24 payments
Mentor Worldwide LLC $93,420 157 payments
Stemline Therapeutics Inc. $43,271 2 payments
Amgen Inc. $3,828 2 payments
NS Pharma, Inc. $3,247 87 payments

Studies the money was for Research payments · program years 2019–2025

STUDY NAME#PET adapted Brentuximab Vedotin and Pembrolizumab in Combination with Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma $2,266,386 2 payments
0000000000000000000000000000000000000000000000000000000000000000217784 $1,572,214 20 payments
217784 $331,955 2 payments
Study name not reported $174,740 2 payments
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors $170,400 1 payment
A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction $93,420 157 payments
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin plus Docetaxel in Triple Negative Breast Cancer NeoPACT $63,900 1 payment
Stml-401-0314 $43,271 2 payments
AMG 160_Ph1b Master Protocol Evaluating AMG 160 in Subjects with mCRPC_20190505 $3,175 1 payment
Randomized, Controlled Clinical Trial (Phase 2B) of Ns-018 Versus Best Available Therapy in Subjects With Primary Or Secondary Myelofibrosis With Severe Thrombocytopenia $1,656 32 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.